[The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma].
Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto). Seven cases were previously untreated. A partial remission was observed only in one patient (6%, confidence limits to 95%: 1-17%). Marked gastrointestinal and hematologic toxicity was registered. Based on this experience the authors are unable to confirm other pilot studies claiming major antitumor activity for MOF-Strepto in the treatment of advanced colo-rectal cancer.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004338:Drug Combinations; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy*; D012673:Semustine / Q000627:therapeutic use*; D013311:Streptozocin / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced; D014750:Vincristine / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D004338:Drug Combinations; D009607:Nitrosourea Compounds; D012673:Semustine; D014750:Vincristine; D013311:Streptozocin; D005472:Fluorouracil
L'association méthyl-CCNU, vincristine, 5-fluoro-uracile et streptozotocine dans le traitement de l'adénocarcinome colo-rectal avancé. Une étude pilote.